Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.

ABSTRACT:

Aim

To estimate the cost-effectiveness of sequential use of the sodium-glucose co-transporter-2 inhibitor empagliflozin and glucagon-like peptide-1 receptor agonist liraglutide after metformin in patients with type 2 diabetes (T2D) from the US payer perspective.

Materials and methods

An economic simulation model with a lifetime horizon was developed to estimate T2D-related complications (including cardiovascular [CV] death, myocardial infarction, stroke, and renal outcomes) using EMPA-REG OUTCOME data or UK Prospective Diabetes Study risk equations, in patients with or without a history of cardiovascular disease (CVD), respectively. Evidence synthesis methods were used to provide effectiveness inputs for empagliflozin and liraglutide. Population characteristics, adverse even

SUBMITTER: Reifsnider OS 

PROVIDER: S-EPMC9305296 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature